RapidAI has received U.S. Food and Drug Administration (FDA) clearance for Aortic Management, part of its Rapid Aortic AI-based software for assessment and management of aortic disease.
Built on the Rapid Enterprise Platform, Rapid Aortic is designed to assist clinicians in quickly and accurately identifying aortic aneurysms, dissections, and other anomalies, according to the San Mateo, CA-based company.
Rapid Aortic is integrated into RapidAI's Rapid Edge Cloud, and all of its modules are integrated into its Rapid Navigator Pro and Rapid mobile and web applications to work together across PACS, EHR, and reporting systems.
The software is designed to enable analysis of all CT scans that include the aorta, including post-treatment and non-contrast studies, and to assist in identifying and tracking pathology, RapidAI added.
